Arcutis Biotherapeutics (ARQT) Cash & Current Investments (2019 - 2026)

Arcutis Biotherapeutics' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $189.5 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 30.18% year-over-year to $189.5 million; the TTM figure through Mar 2026 stood at $189.5 million (up 30.18% YoY), while the FY2025 annual figure was $221.0 million, down 3.06% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $189.5 million, down from $221.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $396.7 million in Q3 2022, with the low at $118.4 million in Q2 2025.
• The 5-year median for Cash & Current Investments is $221.0 million (2025), against an average of $232.3 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments sank 69.61% in 2023, then soared 174.23% in 2024.
• Arcutis Biotherapeutics' Cash & Current Investments stood at $357.2 million in 2022, then sank by 48.38% to $184.4 million in 2023, then climbed by 23.63% to $228.0 million in 2024, then dropped by 3.06% to $221.0 million in 2025, then slipped by 14.23% to $189.5 million in 2026.
• Business Quant data shows ARQT's Cash & Current Investments at $189.5 million in Q1 2026, $221.0 million in Q4 2025, and $191.1 million in Q3 2025.